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This consensus report is the result of a panel discus-
sion during the International Clinically Oriented
ESDR Symposium Urticaria 2000. Urticaria has a pro-
found impact on the quality of life and effective
treatment is required. The most important are non-
sedating H1 antihistamines. They have been proven
to be effective in double-blind controlled studies, but
concentrations higher than those recommended may
be necessary. Due to different urticaria subtypes and
the individual variation in the course of the disease
and response to treatment, however, alternative
therapies may be required. Immunosuppressive
drugs like cyclosporine A and corticosteroids should
not be used long term due to undesirable side-
effects. Key words: antihistamine/treatment/wheal.
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T
his consensus report is the result of a panel discussion
during the International Clinically Oriented ESDR
Symposium ``Urticaria 2000''. With over 100 partici-
pants specializing in the ®eld of urticaria from more
than 15 countries, this consensus includes any possible
regional differences in therapeutic approach.
Although urticaria is elicited by a great diversity of factors and
clinically presents in a highly variable way, its treatment follows the
same principles. The therapy of urticaria is best subdivided into
three basic lines of approach that should be followed in each
patient. These are described below.
Avoidance or elimination of the eliciting stimulus This
approach is the most desirable because it is curative, but it is
unfortunately not applicable in the majority of patients as the exact
eliciting stimulus is frequently unknown. It can, however, be
instituted for the rare patients with IgE-mediated urticaria and for
all patients with physical urticaria. In the latter group the impact of
physical stimuli can be diminished and symptoms ameliorated by
appropriate measures (e.g., cushioning in pressure urticaria). In
chronic urticaria treatment of associated in¯ammatory processes,
including parasitic diseases and cancer, or of food and drug
intolerance can be curative or at least helpful.
Inhibition of mast cell mediator release The next approach
should be aimed at the mast cell as the central effector cell.
Unfortunately, there are only a few effective drugs available to
inhibit mast cell mediator release.
Therapy of target tissues of mast cell mediators Currently,
the most frequently used therapy aims to inhibit the effect of mast
cell mediators on the target tissue and thus at the amelioration or
suppression of symptoms.
The speci®c treatment options in these three categories are
discussed in detail below.
ELICITING STIMULI
With this therapeutic approach, an exact diagnosis is a basic
prerequisite. If remission on elimination or avoidance of the
suspected agent occurs, recurrence of symptoms on re-exposure
provides more proof of its causative nature as spontaneous
remission of urticaria might also occur incidentally on elimination
of a suspected cause.
Drugs When such agents are suspected in the course of diagnosis,
they should be omitted entirely or substituted by another class of
agents if indispensable. Drugs causing pseudoallergic reactions
(prototype being aspirin) cannot only elicit but also aggravate pre-
existing chronic urticaria (WuÈthrich, 1993), so that elimination will
only improve symptoms.
Physical stimuli Avoidance of physical stimuli for the treat-
ment of physical urticaria would appear to be simple. Detailed
information about the physical properties of the respective stimulus
should make the patient suf®ciently knowledgeable to recognize
and control his exposure in normal daily life. Thus, it is important
in dermographic urticaria as well as in delayed pressure urticaria to
point out that pressure is de®ned as force per area and that simple
devices (such as broadening of the handle of heavy bags) may
already be helpful in the prevention of symptoms. Similar
considerations hold for cold urticaria. Here the impact of the
chill factor in cold winds needs to be remembered. For solar
urticaria, the exact identi®cation of the range of eliciting
wavelengths may be important for the appropriate selection of
sunscreens or for the selection of light bulbs with a UVA ®lter;
however, in many patients the threshold for the individual eliciting
stimulus is low and thus the total avoidance of symptoms is virtually
impossible.
Removal of infectious agents and treatment of in¯amma-
tory processes In contrast to physical urticaria where coexisting,
potentially disease-sustaining factors are only found in cold and
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dermographic urticaria, chronic urticaria is often associated with a
variety of in¯ammatory or infectious processes. This is regarded as
signi®cant in some instances. These infections include those of the
gastrointestinal tract like Helicobacter pylori (Wedi and Kapp, 1999)
or bacterial infections of the nasopharynx, which should be treated
appropriately. Parasites, a rare cause of urticaria in industrial
countries, should be eliminated (Henz and Zuberbier, 1998). In the
past intestinal candidosis has been regarded as a highly important
eliciting factor for chronic urticaria (Champion et al, 1969), but
recent ®ndings fail to support a signi®cant causative role (Zuberbier
et al, 1995). Nevertheless, it is recommended that massive
candidosis should be treated.
Apart from infectious diseases, chronic in¯ammatory processes
due to other diverse diseases have been identi®ed as causative for
urticaria in the recent past. This holds particularly for gastritis,
re¯ux esophagitis, or in¯ammation of the bile duct or bile gland
(Bruno et al, 1998, pp 85±89; Zuberbier et al, 1995).
Removal of FceRI autoantibodies There are currently few
reported studies on the treatment of chronic urticaria by removing
autoantibodies. Plasmapheresis has been shown to be of temporary
bene®t in individual, severely affected patients (Grattan et al, 1992;
Greaves, 2000). Alternatively, immunologic treatment with agents
inhibiting antibody formation as one of their actions, e.g.,
cyclosporine (Fradin et al, 1991; Barlow et al, 1993; Toubi et al,
1997; Grattan et al, 2000), or with high-concentration immuno-
globulin infusions (O'Donnell et al, 1998) has been proven to be
helpful. Due to the high cost, these therapies should be reserved for
autoantibody-positive chronic urticaria patients unresponsive to
other forms of treatment.
Dietary management IgE-mediated food allergy is rare in
urticaria (Juhlin, 1981; Zuberbier et al, 1995). If identi®ed, the
speci®c food allergens need to be omitted as far as possible. In a
subgroup of chronic urticaria patients pseudoallergic reactions to
naturally occurring food ingredients and in some cases to food
additives are seen (Juhlin, 1981; Zuberbier et al, 1995; Pfrommer
et al, 1996; Pigatto and Valsecchi, 2000). In these cases a diet
containing only low levels of natural as well as arti®cial food
pseudoallergens should be instituted and maintained for a
prolonged period of at least 3±6 mo. During this time
spontaneous remission is achieved in approximately 50% of
patients. It should be underlined that avoidance of type I
allergens clears urticaria symptoms within 24±48 h if relevant
allergens are rapidly eliminated, whereas in pseudoallergy a diet has
often to be maintained for 2±3 wk before bene®cial effects can be
observed.
MAST CELL DIRECTED THERAPY
At present, the most ef®cient drugs inhibiting mast cell mediator
release are corticosteriods. They should be avoided for long-term
treatment of chronic urticaria, as dosages necessary to suppress
symptoms are usually high with signi®cant side-effects. For acute
urticaria, however, a short course of corticosteroids may be helpful
in reducing disease duration (Zuberbier et al, 1996a). Cyclosporine
A also has a moderate, direct effect on mast cell mediator release
(Stellato et al, 1992), but this drug cannot be recommended as a
standard treatment due to potentially severe adverse effects.
PUVA reduces the numbers of mast cells in the upper dermis. It
has been successfully used in mastocytosis and is helpful in
treatment-resistant patients with this condition (Godt et al, 1997;
Horio, 2000). For the treatment of chronic urticaria, UVA and
UVB treatment for 1±3 mo can be added to the antihistamine
treatment (Hannuksela and Kokkonen, 1985; Olafsson et al, 1986).
Tolerance induction may also be considered under the heading
mast cell directed therapy. This is sometimes used for cold urticaria
and cholinergic urticaria therapy and as a standard treatment for
solar urticaria where even a rush therapy with UVA has been
proven to be effective within 3 d (Beissert et al, 2000).
THERAPY AT THE TARGET ORGAN
Nearly all symptoms of urticaria are mediated by H1-receptors. H1-
receptor antagonists are thus of eminent importance in the
treatment of urticaria. With the increased availability of this
group of substances since the 1950s, urticaria has become one of the
diseases that can be treated effectively with a very low adverse effect
pro®le. The development of second-generation nonsedating or
low-sedating antihistamines has improved the quality of life of
urticaria patients. New generation antihistamines also exert anti-
in¯ammatory effects such as cytokine release from basophils and
mast cells (Lippert et al, 1995, 2000). This may be of additional
bene®t in controlling symptoms in urticaria if these effects occur at
a clinically relevant dosage (Merk et al, 1985). There are some
studies that show the bene®t of a higher concentration of
antihistamines in individual patients (Kontou-Fili et al, 1989;
Zuberbier et al, 1996b), but further investigations in this ®eld are
necessary. The possibility of increased adverse cardiac effects,
especially with terfenadine and astemizole (Lindquist and Edwards,
1997), is a consideration in the choice of the speci®c antihistamine,
especially when using higher concentrations than those recom-
mended by the manufacturers. Further progress with regard to drug
safety was achieved by the development of the antihistamines
cetirizine, fexofenadine, and descarboxyloratadine, which are
cytochrome P450-independent metabolites of earlier antihista-
mines. The highest reported accidental overdose of antihistamine
(50-fold of the prescribed dose of cetirizine in an 18-mo-old boy)
induced no adverse effects other than sleepiness (Ridout and Tariq,
1997). The main drug interactions have been described until
recently for sedating antihistamines in association with drugs
affecting the central nervous system like analgetics, hypnotics,
sedatives, and mood elevating drugs, as well as alcohol. In addition,
MAO inhibitors can prolong and intensify anticholinergic effects.
Some modern antihistamines are also metabolized by cytochrome
P450 enzymes (Renwick, 1999), and increased plasma levels are
observed when there is concomittant treatment with drugs
employing this enzyme system for metabolism such as ketoconazole
or erythromycin.
In summary, considering their good safety pro®le, second-
generation antihistamines must be considered as ®rst line symp-
tomatic treatment for urticaria.
FURTHER THERAPEUTIC POSSIBILITIES
Whereas antihistamines at higher concentrations will control
symptoms in probably more than 95% of patients with urticaria,
alternative treatments are needed for the remaining unresponsive
patients. Many of the alternatives are based on open trials or case
reports. More recent approaches include leukotriene antagonists
(Ellis, 1998; Berkun and Shalit, 2000), interferon (Czarnetzki et al,
1994), or immunoglobulins (O'Donnell et al, 1998).
On the other hand some treatment alternatives formerly
proposed have been shown to be ineffective in double-blind,
placebo-controlled studies and should no longer be used. These
include tranexamic acid and sodium cromoglycate in chronic
urticaria (Laurberg, 1977; Thormann et al, 1980), nifedipin in
dermographic urticaria (Lawlor et al, 1988), and colchicine and
indomethacine in delayed pressure urticaria (Dover et al, 1988;
Lawlor et al, 1989).
Table I summarizes the current standard drug treatment and
alternatives in several subtypes of urticaria.
Because the severity of urticaria may ¯uctuate, and because
spontaneous remission may occur at any time, it is recommended
that the necessity for continued or alternative drug treatment
should be re-evaluated every 3±6 mo.
CONCLUSION
The quality of life in urticaria is severely affected and management
of the disease should therefore be prompt and with close
cooperation between patient and physician. Due to the high
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variability of disease severity, an individual approach is necessary for
each patient. As a ®rst line, triggering factors should be avoided as
far as possible and any associated diseases should be treated. In the
majority of patients, symptomatic pharmacologic treatment is
possible with new generation antihistamines, with a very low
adverse effect pro®le and good patient compliance. In rare,
nonresponding patients higher concentrations and alternative
medication should be tried. Most of these, such as corticosteroids
or cyclosporine, should be reserved for severely affected patients
because of their unfavorable adverse effect pro®le.
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